Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94626794 | 9462679 | 4 | F | 20160711 | 20130816 | 20160713 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-19175140 | BRISTOL MYERS SQUIBB | 25.00 | YR | M | Y | 0.00000 | 20160713 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94626794 | 9462679 | 1 | PS | ARIPIPRAZOLE. | ARIPIPRAZOLE | 1 | Unknown | 5 MG, QD | Y | 21436 | 5 | MG | TABLET | QD | |||||
| 94626794 | 9462679 | 2 | I | CLOZAPINE. | CLOZAPINE | 1 | Unknown | STOPPED ON JUNE 2011, DOSE INCREASED TO 800MG/DAY AND DECREASED TO 500MG/DAY. | Y | 0 | 500 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 94626794 | 9462679 | 1 | Schizophrenia |
| 94626794 | 9462679 | 2 | Schizophrenia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 94626794 | 9462679 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 94626794 | 9462679 | Constipation | |
| 94626794 | 9462679 | Intestinal obstruction | |
| 94626794 | 9462679 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 94626794 | 9462679 | 1 | 201110 | 201111 | 0 | |
| 94626794 | 9462679 | 2 | 201009 | 0 |